Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection

International Journal of Antimicrobial Agents

Volumn 22, Issue SUPPL. 2, 2003, Pages 65-72

  Hooton, Thomas M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cystitis; Empirical therapy of UTI; Fluoroquinolones; Nitrofurantoin; Pyelonephritis; Trimethoprim sulphamethoxazole

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CEFEPIME; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CYSTITIS; ESCHERICHIA COLI; HEALTH CARE COST; HUMAN; LIVER INJURY; LIVER TOXICITY; META ANALYSIS; NONHUMAN; PHYSICIAN; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PYELONEPHRITIS; PYURIA; RISK FACTOR; SIDE EFFECT; STAPHYLOCOCCUS SAPROPHYTICUS; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 0141758345     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00238-3     Document Type: Article

References (50)

1. Hooton T.M., Stamm W.E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North Am. 11:1997;551-581.
2. Talan D.A., Stamm W.E., Hooton T.M., et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. J. Am. Med. Assoc. 283:2000;1583-1590.
3. Brumfitt W., Hamilton-Miller J.M. A review of the problem of urinary infection management and the evaluation of a potential new antibiotic. J. Antimicrob. Chemother. 13:(Suppl. B):1984;S121-S133.
4. Mabeck C.E. Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgrad. Med. J. 48:1972;69-75.
5. Nicolle L.E. Pivmecillinam in the treatment of urinary tract infections. J. Antimicrob. Chemother. 46:(Suppl. S1):2000;35-39.
6. Christiaens T.C., De Meyere M., Verschraegen G., Peersman W., Heytens S., De Maeseneer J.M. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br. J. Gen. Pract. 52:2002;708-710.
7. Noskin G.A., Zembower T., Chmielewski J., Tang P., La Rosa M., Peterson L.R. Disappearance of the 'uncomplicated' urinary tract infection: the impact of emerging resistance. Clin. Drug Invest. 21:(Suppl. 1):2001;13-20.
8. Freedman LR, Andriole VA. The long-term follow-up of women with urinary tract infections. Proc 5th Int Congr Neph (Mexico 1972), Basel, Karger. 1974. 3:230.
9. Gupta K., Sahm D.F., Mayfield D., Stamm W.E. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin. Infect. Dis. 33:2001;89-94.
10. Kahlmeter G. The ECO-SENS project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J. Antimicrob. Chemother. 46:(Suppl. 1):2000;15-22.
11. Gupta K., Hooton T.M., Stamm W.E. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. 135:2001;41-50.
12. Karlowsky J.A., Kelly L.J., Thornsberry C., Jones M.E., Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 46:(8):2002;2540-2545.
13. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS project. J. Antimicrob. Chemother. 51:2003;69-76.
14. Karlowsky J.A., Thornsberry C., Jones M.E., Sahm D.F. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin. Infect. Dis. 36:2003;183-187.
15. Zhanel G.G., Hoban D.J., Karlowsky J.A. Nitrofurantoin is active against vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2001;324-326.
16. Gupta K., Scholes D., Stamm W.E. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. J. Am. Med. Assoc. 281:1999;736-738.
17. Brown P.D., Freeman A., Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin. Infect. Dis. 34:2002;1061-1066.
18. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin. Infect. Dis. 29:1999;745-758.
19. Masterton R.G., Bochsler J.A. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J. Antimicrob. Chemother. 35:1995;129-137.
20. McCarty J.M., Richard G., Huck W., et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am. J. Med. 106:1999;292-299.
21. Raz R., Chazan B., Kennes Y., et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 34:2002;1165-1169.
22. Wright S.W., Wrenn K.D., Haynes M.L. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J. Gen. Intern. Med. 14:1999;606-609.
23. Steinke D.T., Seaton R.A., Phillips G., MacDonald T.M., Davey P.G. Factors associated with trimethoprim-resistant bacteria isolated from urine samples. J. Antimicrob. Chemother. 43:1999;841-843.
24. Steinke D.T., Seaton R.A., Phillips G., MacDonald T.M., Davey P.G. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J. Antimicrob. Chemother. 47:2001;781-787.
25. Hooton T.M., Winter C., Tiu F., Stamm W.E. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. J. Am. Med. Assoc. 273:1995;41-45.
26. Wagenlehner f., Stower-Hoffmann J., Schneider-Brachert W., Naber K.G., Lehn N. Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology. Int. J. Antimicrob. Agents. 15:2000;207-211.
27. Horcajada J.P., Vila J., Moreno-Martinez A., et al. Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J. Antimicrob. Chemother. 49:2002;55-59.
28. Hooton T.M., Latham R.H., Wong E.S., Johnson C., Roberts P.L., Stamm W.E. Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis. Antimicrob. Agents Chemother. 33:1989;1308-1312.
29. Schaeffer A.J., Sisney G.A. Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora. J. Urol. 133:1985;628-630.
30. Cunha B.A. Nitrofurantoin: an update. Obstet. Gynecol. Survey. 44:1989;S399-S406.
31. Gossius G. Single-dose nitrofurantoin therapy for urinary tract infections in women. Curr. Ther. Res. 35:1984;925.
32. Pelletier L.L., Michalak D.P., Carter J.Z., et al. A comparison of macrobid (nitrofurantoin monohydrate/macrocrystals) and macrodantin (nitrofurantoin macrocrystals) in the treatment of acute episodes of uncomplicated lower urinary tract infection. Adv. Ther. 9:1992;32.
33. Spencer R.C., Moseley D.J., Greensmith M.J. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J. Antimicrob. Chemother. 33:(Suppl. A):1994;121-129.
34. McOsker CC, Pollack JR, Andersen JA. Inhibition of bacterial protein synthesis by nitrofurantoin macrocrystals: an explanation for the continued efficacy of nitrofurantoin, In: Harrison LH, editor. Management of urinary tract infection, royal society of medicine services international congress and symposium series, No. 154. London: Royal Society of Medicine Svcs Ltd, 1990. pp. 33-44.
35. Hooton T.M., Stamm W.E. The vaginal flora and UTIs. Mobley H.L.T., Warren J.W. UTIs: molecular pathogenesis and clinical management. 1996;67-94 ASM Press, Washington, DC.
36. Physicians' desk reference. Medical Economics Company, Montvale NJ, 2002.
37. Guay D.R. An update on the role of nitrofurans in the management of urinary tract infections. Drugs. 61:2001;353-364.
38. Brumfitt W., Hamilton-Miller J.M.T. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience. J. Antimicrob. Chemother. 42:1998;363-371.
39. Leibovici L. Antibiotic treatment for cystitis. Br. J. Gen. Pract. 52:2002;708-710.
40. Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infection. Int. J. Antimicrob. Agents. 11:1999;247-251.
41. Naber K.G. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother. 46:(Suppl. A):2000;49-52.
42. Lautenbach E., Larosa L.A., Kasbekar N., Peng H.P., Maniglia R.J., Fishman N.O. Fluoroquinolone utilization in the emergency department of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch. Intern. Med. 163:2003;601-605.
43. Kavatha D., Giamarellou H., Alexiou Z., et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob. Agents Chemother. 47:2003;897-900.
44. Fosfomycin for urinary tract infections, Med. Lett. 1997;39:66-68.
45. Huang E.S., Stafford R.S. National patterns in the treatment of urinary tract infection in women by ambulatory care physicians. Arch. Intern. Med. 162:2002;41-47.
46. Stamm W.E., McKevitt M., Counts G.W. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann. Intern. Med. 106:1987;341-345.
47. Barza M., Ioannidis J.P., Cappelleri J.C., Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br. Med. J. 312:1996;338-345.
48. Bergeron M.G. Treatment of pyelonephritis in adults. Med. Clin. North Am. 79:1995;619-649.
49. Bergeron M.G., Marois Y. Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis. Kidney Int. 30:1986;481-487.
50. Caceres V.M., Stange K.C., Kikano G.E., et al. The clinical utility of a day of hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of pyelonephritis. J. Fam. Pract. 39:1994;337-339.